HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DeLauro Renews Push To Give FDA Mandatory Recall Authority For Drugs

Executive Summary

"FDA’s failure to stop companies from selling ranitidine makes the United States government complicit in exposing infants and adults to the risk of cancer," says Rep. DeLauro in letter to FDA and HHS. She also re-introduced legislation proposing FDA have mandatory recall authority for drugs.

You may also be interested in...

DeLauro and Durbin's Latest Food Safety Agency Legislation Would Carve Out FDA Pieces Only

In their fifth attempt, Rep. DeLauro an Sen. Durbin are trying something new to create an independent food safety agency by splitting off food safety departments from the FDA.

House Appropriators Say Infant Formula Shortage Signals Restructuring Needed At US FDA

"Many of the problems facing [the FDA] can be solved through strong leadership rather than more money,” says Rep. Andy Harris during Appropriations subcommittee hearing, Committee Chairwoman Rosa DeLauro continues her criticism of FDA's regulation of industries under its oversight, saying a "structural problem" caused infant formula shortage.    

DeLauro Whistles For Investigation Of US FDA Response To Whistleblower Report On Abbott Formula Facility

Appropriations chairwoman Rosa DeLauro wants answers from HHS Office of Inspector General about FDA’s response to whistleblower report of contamination at Abbott Nutrition infant formula facility. Report described pattern of unsatisfactory quality control practices at the plant.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts